Evidence map›Paper›PMID 38310400›Full record

ReviewCurrent medicinal chemistry2025

Multifaceted Nature of HuR in Atherosclerosis Development.

Yan-Xia Wang, Hong-Yu Zheng, Kun Zhou, Hai-Lin Xie, Zhong Ren, Hui-Ting Liu, Huan Liu, Zhi-Xiang Zhou, Zhi-Sheng Jiang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Research (Washington, D.C.) · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yan-Xia WangInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Hong-Yu ZhengInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Kun ZhouInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Hai-Lin XieInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Zhong RenInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Hui-Ting LiuInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Huan LiuInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Zhi-Xiang ZhouInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.
Zhi-Sheng JiangInstitute of Cardiovascular Disease, Key Lab for Arteriosclerology of Hunan Province, International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province, Hengyang Medical College, University of South China, Hengyang, 421001, China.ORCID 0000-0001-5685-6228
University of South China · CN

Funding

International Joint Laboratory for Arteriosclerotic Disease Research of Hunan Province 2018WK4031National Natural Science Foundation of China 81670429, 91839103Postgraduate Scientific Research Innovation Project of Hunan Province CX20221022Special Funding for Construction of Innovative Provinces in Hunan Province 2020SK2105
6 · The paper itself

Abstract

HuR (Human antigen R) is an RNA binding protein (RBP) that specifically binds to certain RNA sequences, influencing post-transcriptional regulation. HuR is primarily involved in tumor regulation, as well as cell growth, proliferation, inflammation, and angiogenesis. HuR is implicated in endothelial activation, smooth muscle proliferation, inflammatory response, macrophage apoptosis, lipid regulation, and autophagy, playing a crucial regulatory role in atherosclerosis. Accumulating evidence suggests that HuR has dual roles in AS. On the one hand, HuR expedites the development of AS by facilitating endothelial activation, smooth muscle proliferation, and inflammation. On the contrary, it exerts beneficial effects by reducing macrophage apoptosis, regulating lipid efflux, and increasing autophagy. In this review, we aim to provide a comprehensive summary of the role of HuR in the development of AS by examining its involvement in cellular mechanisms, inflammation, autophagy, and apoptosis. Additionally, we discuss the mechanisms of drugs that target HuR, with the goal of offering new perspectives for the treatment of AS.

Indexed as

AtherosclerosisELAV-Like Protein 1AnimalsApoptosisAutophagyHumansInflammationELAVL1 protein, humanELAV-Like Protein 13‘ UTRAtherosclerosisembryonic lethal.endothelial cellshuman antigen Rnucleoplasmic translocation

Identifiers

PMID38310400
OpenAlexW4391522281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.